World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
78
Citations
23685
World Ranking
17999
National Ranking
8972

Overview

Maurizio Zangari is affiliated with the University of Arkansas for Medical Sciences in the United States. Their research primarily focuses on hematology and oncology, with a particular emphasis on multiple myeloma. The scientist has contributed extensively to the medical literature, with published work spanning medicine, biochemistry, genetics, and molecular biology.

The main topics covered in their research include:

  • Multiple Myeloma Research and Treatments
  • Protein Degradation and Inhibitors
  • CAR-T cell therapy research
  • Cancer Treatment and Pharmacology
  • Peptidase Inhibition and Analysis
  • Monoclonal and Polyclonal Antibodies Research
  • Chronic Lymphocytic Leukemia Research

Their work is published predominantly in several recurring journals, which present a pattern of specialized scientific communication. Frequent publication venues include:

  • Blood
  • Blood Advances
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Clinical Oncology
  • Blood Cancer Journal

Zangari's research partnerships involve numerous coauthors with whom they have a significant collaborative footprint. Regular coauthors include Carolina Schinke, Frits van Rhee, Sharmilan Thanendrarajan, Samer Al Hadidi, and John D. Shaughnessy, reflecting a network of collaboration within the field of hematology and oncology.

The scientist has contributed to various studies covering molecular and clinical aspects of multiple myeloma. Notable recent papers include:

  • "The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma," 2021, Nature Communications
  • "Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis," 2023, Blood Advances
  • "Long-term outcomes after autologous stem cell transplantation for multiple myeloma," 2020, Blood Advances
  • "Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study," 2024, Blood Cancer Journal
  • "Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials," 2020, PLoS Medicine

Their body of work contributes to understanding the biological mechanisms underlying multiple myeloma progression and treatment response. This includes examining molecular pathways, clinical outcomes post-transplantation, infection risks with novel therapies, and bone marrow microenvironment influences.

Maurizio Zangari's publication record and collaborative network reflect an active engagement in advancing the knowledge and treatment approaches within hematology, particularly focused on multiple myeloma. Their cross-disciplinary impact spans medicine and molecular biology, integrating clinical insights with molecular research methods.

Best Publications

  • The molecular classification of multiple myeloma

    Fenghuang Zhan;Yongsheng Huang;Yongsheng Huang;Simona Colla;Simona Colla;James P. Stewart;James P. Stewart

  • A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1

    John D. Shaughnessy;Fenghuang Zhan;Bart E. Burington;Yongsheng Huang

  • Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

    A. Palumbo;S. V. Rajkumar;M. A. Dimopoulos;P. G. Richardson

  • Thalidomide and hematopoietic-cell transplantation for multiple myeloma

    Bart Barlogie;Guido Tricot;Elias Anaissie;John Shaughnessy

  • Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells

    Fenghuang Zhan;Johanna S. Hardin;Bob Kordsmeier;Klaus Bumm

  • Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.

    Bart Barlogie;Raman Desikan;Raman Desikan;Paul Eddlemon;Paul Eddlemon;Trey Spencer;Trey Spencer

  • Treatment of multiple myeloma

    Bart Barlogie;John D Shaughnessy;Guido Tricot;Joth Jacobson

  • Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

    Maurizio Zangari;Elias Anaissie;Bart Barlogie;Ashraf Badros

  • Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications

    Ronald Walker;Bart Barlogie;Jeffrey Haessler;Guido Tricot

  • Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.

    Fenghuang Zhan;Bart Barlogie;Varant Arzoumanian;Yongsheng Huang

  • Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities.

    Raman Desikan;Bart Barlogie;Bart Barlogie;Jeffrey Sawyer;Jeffrey Sawyer;Dan Ayers;Dan Ayers

  • Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3

    Bart Barlogie;Elias Anaissie;Frits Van Rhee;Jeffrey Haessler

  • Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing

    L. Rasche;S. S. Chavan;O. W. Stephens;P. H. Patel

  • Results of autologous stem cell transplant in multiple myeloma patients with renal failure.

    Ashraf Badros;Bart Barlogie;Eric Siegel;Jennifer Roberts

  • Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy

    Maurizio Zangari;Eric Siegel;Bart Barlogie;Elias Anaissie

  • Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.

    Maurizio Zangari;Bart Barlogie;Elias Anaissie;Fariba Saghafifar

  • NEK2 Induces Drug Resistance Mainly through Activation of Efflux Drug Pumps and Is Associated with Poor Prognosis in Myeloma and Other Cancers

    Wen Zhou;Ye Yang;Ye Yang;Jiliang Xia;Jiliang Xia;He Wang;He Wang

  • Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities.

    Bart Barlogie;Mauricio Pineda-Roman;Frits van Rhee;Jeff Haessler

  • Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years.

    Ashraf Badros;Bart Barlogie;Eric Siegel;Christopher Morris

  • ORIGINAL ARTICLE Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

    A Palumbo;SV Rajkumar;MA Dimopoulos;PG Richardson

Frequent Co-Authors

Frits van Rhee
Frits van Rhee University of Arkansas for Medical Sciences
Bart Barlogie
Bart Barlogie Mount Sinai Hospital
Gareth J. Morgan
Gareth J. Morgan Boston University
Guido Tricot
Guido Tricot University of Iowa
Faith E. Davies
Faith E. Davies New York University Langone Medical Center
Joshua Epstein
Joshua Epstein University of Arkansas for Medical Sciences
Elias Anaissie
Elias Anaissie University of Cincinnati
Brian A Walker
Brian A Walker Indiana University – Purdue University Indianapolis
John D. Shaughnessy
John D. Shaughnessy University of Arkansas for Medical Sciences
John Crowley
John Crowley Washington University in St. Louis

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative online degrees can open valuable career options in healthcare beyond traditional medical studies. For students interested in patient care but looking for more accessible entry, consider nursing schools that don't require teas. These programs remove some standardized testing barriers, making the path to a nursing career more attainable.

If you’re drawn to the organizational side of healthcare, there are reputable online health administration programs that offer flexibility alongside a fast-track to leadership roles in hospitals, clinics, and insurance companies.

Registered nurses considering career advancement should look into RN to NP programs online. These bridge programs allow RNs to become nurse practitioners, expanding their scope of practice and opening doors to higher-level positions.

Alternatively, those passionate about diet and wellness may wish to explore an online BS in nutrition, preparing for diverse roles in healthcare, community wellness, and research.

Best Scientists Citing Maurizio Zangari

Trending Scientists

Recently Published Articles